Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture of Commercial Operations

SAN RAMON, Calif., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
December 11, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Departure of Chief Financial Officer

SAN RAMON, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
December 08, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN RAMON, Calif., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
December 04, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Settlement of Securities Class Action and Shareholder Derivative Lawsuits

SAN RAMON, Calif., Dec. 4, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
November 30, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Oppenheimer 26th Annual Healthcare Conference

SAN RAMON, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
November 20, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Completes Divestiture of Abstral(R) (fentanyl) Sublingual Tablets as Part of Strategic Focus on Its Immunotherapy Pipeline

SAN RAMON, Calif., Nov. 20, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology...
November 09, 2015 16:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its Clinical Development Programs With Planned Divestiture of the Commercial Business

Clinical development immunotherapy programs make significant advances with new trials including a NeuVax™ Phase 2 clinical trial in DCIS and encouraging Phase 2a data for...
November 09, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting

SAN RAMON, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
November 06, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN RAMON, Calif., Nov. 6, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...
October 30, 2015 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical Officer

SAN RAMON, Calif., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right